Bacteriophages are promising antibacterial agents for managing acne vulgaris caused by Cutibacterium acnes, particularly given increasing antibiotic resistance. Here, we isolated and characterized two lytic Cutibacterium phages, NS-ph1 and NS-ph2, from acne lesions. Both bacteriophages exhibited a broad lytic spectrum, with a high activity against 27 C. acnes strains. Adsorption assays indicated rapid attachment and one-step growth experiments revealed latent periods of 4 h (NS-ph1) and 2 h (NS-ph2) and burst sizes of 70 and 59 PFU per infected cell, respectively. After long-term storage at room temperature, both phages retained infectivity for 3 months. Genome sequencing revealed linear dsDNA genomes of 29,490 bp (NS-ph1) and 29,189 bp (NS-ph2) with 51 and 46 predicted ORFs, respectively, and no tRNAs. No genes associated with lysogeny, toxins, or antibiotic resistance were detected. Comparative genomics placed both phages within the genus Pahexavirus. Together, these data expand the diversity of Pahexavirus and provide two well-characterized lytic candidates for further evaluation in anti-acne phage therapy.
Oral diseases cause a wide range of difficulties for patients. The natural bioactive compound dihydroquercetin (DHQ), which demonstrates regenerative, anti-inflammatory, antioxidative, and antibacterial effects, is of interest for their treatment. The combination of DHQ and l-lysine DHQ is “very easily soluble”. The aim of this study is to compare orally disintegrating tablets based on raw DHQ and on the DHQ-l-lysine composition. Following the guidelines outlined in the ICH Q8 (R2) standard, a fundamental quality target product profile and critical quality attributes were established. The Sediment Delivery Model (SeDeM) method was used to evaluate the substance suitability for direct compression. Quantitative analysis of the DHQ release was carried out by high-performance liquid chromatography, and infrared (IR) spectroscopy was performed using the attenuated total reflection technique without any prior sample preparation. The DHQ-l-lysine composition shows improved dimensions (4.12) and flowability (4.96). The release rate constants (Krelease) were 8.14 and 3.61%/min, while the half-release periods (t50%) were 6.14 and 13.85 min for tablets with DHQ (TF1) and DHQ-l-lysine compositions (TF2), respectively. The difference factor (f1) and similarity factor (f2) were 23.43% and 43.37%, respectively. The tablet manufacture had a critical impact on the characteristics of the IR spectra (the r values −0.8785 and 0.5474 for TF1 and TF2). The conducted study demonstrates the promise of using DHQ-l-lysine composition for developing effective dosage forms with improved technological characteristics and controlled release of the active substance.
The effect of administration routes (oral and rectal) on the pharmacokinetics of Salmonella phage SE40 and Escherichia phage V18 was studied. To detect phages in biomaterial (blood, urine, and feces), the Spot-test, Gratia, and double-nested polymerase chain reaction methods were used. Systemic action of the studied phages with both routes of administration, beginning 15–30 min after administration, was demonstrated. The phages persisted for up to 24 h after both oral and rectal administration. However, the concentration in the blood was higher after oral administration, while concentrations in urine and feces were higher after rectal administration. The need to protect phages from the acidic contents of the stomach was confirmed.